Clinical Trials Logo

Eradication clinical trials

View clinical trials related to Eradication.

Filter by:
  • None
  • Page 1

NCT ID: NCT05586464 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This study is a prospective randomized case-control study. Six hundred patients who were firstly diagnosed as Helicobacter pylori infection will be selected, and then randomly assigned into case group and control group. Patients in control group take bismuth quadruplicate for 14 days. Patients in case group take Ban xia xie xin Decoction and bismuth agent quadruple for 14 days. Exhalation test or stool Helicobacter pylori antigen detection were used to assess the eradication rate of Helicobacter pylori 30 days (the 45th day) after treatment; Adverse reactions were evaluated on the first day (15th day) and the 30th day (45th day) after treatment. The eradication rate of Helicobacter pylori and the adverse drug reactions during the medication will be evaluated. The effect of Ban xia xie xin Decoction and bismuth quadruple based on furazolidone on the eradication of helicobacter pylori infection will be explored.

NCT ID: NCT04618159 Completed - Eradication Clinical Trials

Does Helipyl Eradicate

Helipyl
Start date: February 10, 2019
Phase: Phase 4
Study type: Interventional

Helipyl is on the market; actually it is a post-biotic because it is a killed Lactobacillus reuteri DSMZ 17648. The aim is to demonstrate (or not) that this product eradicates helicobacter, which it claims to do.

NCT ID: NCT02934048 Not yet recruiting - Helicobacter Pylori Clinical Trials

Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies. However, due to the increasing resistance rates to antibiotics, failures of H. pylori eradication get more and more common. Thus, rescue therapy for persistent H. pylori infection is becoming a grand challenge the investigators have to face.

NCT ID: NCT00596401 Completed - Gastric Cancer Clinical Trials

The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

Start date: September 2007
Phase:
Study type: Observational

Recently, the preventive effect of Helicobacter pylori (Hp) eradication treatment on the incidence of gastric cancer has been reported. By Hp eradication treatment being performed for Hp-infected people in Iijima town, we will evaluate whether the incidence of gastric cancer and/or the medical care cost can be reduced as compared with those in the previous years.